Toh Tan Boon, Lim Jhin Jieh, Chow Edward Kai-Hua
Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, MD6 #12-01, Singapore, 117599, Singapore.
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Drive, Level 5, Singapore, 117597, Singapore.
Clin Transl Med. 2019 May 6;8(1):13. doi: 10.1186/s40169-019-0230-0.
In recent years, large scale genomics and genome-wide studies using comprehensive genomic tools have reshaped our understanding of cancer evolution and heterogeneity. Hepatocellular carcinoma, being one of the most deadly cancers in the world has been well established as a disease of the genome that harbours a multitude of genetic and epigenetic aberrations during the process of liver carcinogenesis. As such, in depth understanding of the cancer epigenetics in cancer specimens and biopsy can be useful in clinical settings for molecular subclassification, prognosis, and prediction of therapeutic responses. In this review, we present a concise discussion on recent progress in the field of liver cancer epigenetics and some of the current works that contribute to the progress of liver cancer therapeutics.
近年来，使用综合基因组工具进行的大规模基因组学和全基因组研究重塑了我们对癌症进化和异质性的理解。肝细胞癌是世界上最致命的癌症之一，已被确认为一种基因组疾病，在肝癌发生过程中存在大量遗传和表观遗传异常。因此，深入了解癌症标本和活检中的癌症表观遗传学，在临床环境中对分子亚分类、预后以及治疗反应预测可能会有所帮助。在这篇综述中，我们简要讨论了肝癌表观遗传学领域的最新进展以及一些推动肝癌治疗进展的当前研究工作。
